US 2025/0059290 A1Published application

Anti-ox40 antagonistic antibodies for the treatment of autoimmune diseases

AssigneeIchnos Sciences SA

InventorsJonathan Back, Ernst Kriehuber

Life of this patent

Estimating the term…

Abstract

The present invention relates to the use GBR830 for the treatment of OX40 mediated disorders and in particular to the modulation of Th1 and/or Th2 and/or Th17/Th22 markers.

Claims7

Dependent claims

A method of treating or preventing an OX40-mediated disorder comprising administering to a subject in need thereof an anti-OX40 antagonist antibody, wherein said antagonist antibody induces modulation of Th1 and/or Th2 and/or Th17/Th22 markers.

Dependencies are inferred from the claim text.

Facts

Application: 18/619,805Filed 28 Mar 2024
Priority: EP 18173318.918 May 2018
Published: 20 Feb 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07K 16/2878
Against receptors, cell surface antigens or cell surface determinants: against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
A61P 37/02
Drugs for immunological or allergic disorders: immunomodulators
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
C07K 2317/21
Characterized by taxonomic origin: from primates, e.g. man

Family

Application17/056,168Continuation · filed 17 Nov 2020
Application18/619,805Continuation
US 2021/0214453 A1Published application
US 2025/0059290 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results